Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKI03V
|
|||
| Drug Name |
OV101
|
|||
| Synonyms |
Gaboxadol
Click to Show/Hide
|
|||
| Indication | Angelman syndrome [ICD-11: LD90.0; ICD-10: Q93.5] | Phase 3 | [1] | |
| Fragile X syndrome [ICD-11: LD55; ICD-10: Q99.2] | Phase 2 | [2] | ||
| Company |
Ovid Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor (GABAR) | Target Info | Agonist | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03882918) An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03697161) A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome. U.S.National Institutes of Health. | |||
| REF 3 | Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Front Pharmacol. 2021 Oct 8;12:757825. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.